50803-23-1

Usage

Uses

Used in Pharmaceutical Industry:
4-Bromo-3-chlorosulfonyl-benzoic acid is used as a key intermediate for the synthesis of various pharmaceutical compounds. Its unique structure and strong acidic properties enable the development of new drugs with improved therapeutic effects and reduced side effects.
Used in Agrochemical Industry:
In the agrochemical industry, 4-Bromo-3-chlorosulfonyl-benzoic acid is utilized as a building block for the creation of novel agrochemicals. Its versatile chemical properties allow for the development of more effective and environmentally friendly pesticides and herbicides.
Used in Organic Synthesis:
4-Bromo-3-chlorosulfonyl-benzoic acid is employed as a valuable reagent in organic synthesis due to its strong acidic properties. It facilitates various chemical reactions, leading to the formation of new organic compounds with potential applications in various fields.
Used in Chemical Research:
As a versatile chemical compound, 4-Bromo-3-chlorosulfonyl-benzoic acid is used in chemical research to explore its properties and potential applications. Its unique structure and reactivity make it an interesting subject for studying new reaction mechanisms and developing innovative synthetic methods.

InChI:InChI=1/C7H4BrClO4S/c8-5-2-1-4(7(10)11)3-6(5)14(9,12)13/h1-3H,(H,10,11)

Upstream product

• 586-76-5 4-Bromobenzoic acid 
• 586-75-4 4-chlorobenzoyl chloride 

Downstream Products

• 300383-13-5 4-bromo-3-(morpholinosulfonyl)benzoic acid 
• 300383-12-4 4-bromo-3-(piperidine-1-sulfonyl)-benzoic acid 
• 926199-51-1 4-bromo-3-(tert-butylsulfamoyl)benzoic acid 
• 168969-13-9 2-bromo-5-carbomethoxybenzenesulfonyl chloride 

Relevant academic research and scientific papers

Synthesis of multifunctional metal-organic frameworks and tuning the functionalities with pendant ligands

A series of multifunctional metal-organic frameworks (MOFs), SNU-170-SNU-176, has been synthesized using ligands, in which various functional pendants such as -NH2, -SMe, -OMe, -OEt, -OPr, and -OBu are attached to the phenyl ring of 4-(2-carboxyvinyl)benz

RAD51 INHIBITORS

This application is directed to inhibitors of RAD51 represented by the following structural formula, (I), and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.

Development of a reversible fluorescent probe for reactive sulfur species, sulfane sulfur, and its biological application

We report a reversible off/on fluorescent probe for monitoring concentration changes of sulfane sulfur by utilizing the unique ability of sulfane sulfur to bind reversibly to other sulfur atoms and the intramolecular spirocyclization reaction of xanthene dyes. It reversibly visualized sulfane sulfur in living A549 cells and primary-cultured hippocampal astrocytes.

METHODS OF TREATING CANCER USING RAD51SMALL MOLECULE STIMULATORS

Methods of killing or inhibiting the growth cancer cells and tumors and of treating cancer by administering compounds that stimulate the activity of RAD51. Cells overexpressing RAD51 or with other imbalances in homologous recombination machinery are parti

Structure optimization of 2-benzamidobenzoic acids as PqsD inhibitors for Pseudomonas aeruginosa infections and elucidation of binding mode by SPR, STD NMR, and molecular docking

Pseudomonas aeruginosa employs a characteristic pqs quorum sensing (QS) system that functions via the signal molecules PQS and its precursor HHQ. They control the production of a number of virulence factors and biofilm formation. Recently, we have shown that sulfonamide substituted 2-benzamidobenzoic acids, which are known FabH inhibitors, are also able to inhibit PqsD, the enzyme catalyzing the last and key step in the biosynthesis of HHQ. Here, we describe the further optimization and characterization of this class of compounds as PqsD inhibitors. Structural modifications showed that both the carboxylic acid ortho to the amide and 3′-sulfonamide are essential for binding. Introduction of substituents in the anthranilic part of the molecule resulted in compounds with IC50 values in the low micromolar range. Binding mode investigations by SPR with wild-type and mutated PqsD revealed that this compound class does not bind into the active center of PqsD but in the ACoA channel, preventing the substrate from accessing the active site. This binding mode was further confirmed by docking studies and STD NMR.

HEPATITIS B ANTIVIRAL AGENTS

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS

The invention relates to N-hydroxylsulfonamide derivatives for formula (I), (II) or (III), in which the variables are as defined in the claims, that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. N-hydroxylsulfonamide derivatives release HNO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of the functional groups on the N-hydroxylsulfonamide derivatives.

SULFAMOYL BENZAMIDES AS CANNABINOID RECEPTOR MODULATORS

Novel sulfamoyl benzamide compounds, pharmaceutical compositions containing the sulfamoyl benzamide compounds, and methods of their pharmaceutical use are disclosed. In certain embodiments, the sulfamoyl benzamide compounds are agonists and/or ligands of

Sulfamoyl benzamide derivatives and methods of their use

Novel sulfamoyl benzamide compounds, pharmaceutical compositions containing the sulfamoyl benzamide compounds, and methods of their pharmaceutical use are disclosed. In certain embodiments, the sulfamoyl benzamide compounds are agonists and/or modulating ligands of cannabinoid receptors and may be useful, inter alia, for treating and/or preventing pain, gastrointestinal disorders, inflammation, auto-immune diseases, ischemic conditions, immune-related disorders, hypertension, neurological disorders, and neurodegenerative diseases, for providing cardioprotection against ischemic and reperfusion effects, for inducing apoptosis in malignant cells, for inhibiting mechanical hyperalgesia associated with nerve injury, and as an appetite stimulant.

TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS

Guanidine derivatives having a condensed tricyclic ring of formula 1: are disclosed, wherein U is C(O), CRaRb, O, NRa or S(O)m V is CRaRb or NRa; W is S(O)m ; wherein Ra is H, alkyl, cycloalkyl, alkenyl or aralkyl; Rb is H, alkyl, OH, ORa or OCORa, and m is the integer 0, 1 or 2; R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein with the proviso that at least one of R1, R2, R3, R4, R5, R6, R7 or R8 is guanidino or guanidino carbonyl. These derivatives are sodium-proton exchange inhibitors and are useful as medicaments for the treatment of, for example, organ disorders associated with ischemia and reperfusion, cardiac arrhythmia, cardiac hypertrophy, hypertension, cell proliferative disorders and diabetes.